BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 10326692)

  • 1. Alternating chemotherapy and accelerated split-course irradiation in locally advanced nonsmall cell lung carcinoma.
    Pignon T; Ruggieri S; Boutin C; Gouvernet J; Irisson M; Juin P; Astoul P
    Cancer; 1999 May; 85(10):2144-50. PubMed ID: 10326692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
    Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
    Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
    Park J; Ahn YC; Kim H; Lee SH; Park SH; Lee KE; Lim DH; Park J; Kim K; Jung CW; Im YH; Kang WK; Lee MH; Park K
    Lung Cancer; 2003 Nov; 42(2):227-35. PubMed ID: 14568691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
    Blanke C; DeVore R; Shyr Y; Epstein B; Murray M; Hande K; Stewart S; Johnson D
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):111-6. PubMed ID: 9054884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
    Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
    Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.
    Chen LM; Ignacio L; Jacobs R; Kozloff M; Telfer M; Elahi R; Evans R; Vijayakumar S
    Radiat Oncol Investig; 1999; 7(1):49-53. PubMed ID: 10030624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
    Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
    Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
    J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M; Chapman R; Kim JH
    Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer.
    Ardizzoni A; Grossi F; Scolaro T; Giudici S; Foppiano F; Boni L; Tixi L; Cosso M; Mereu C; Ratto GB; Vitale V; Rosso R
    Br J Cancer; 1999 Sep; 81(2):310-5. PubMed ID: 10496358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.